Trial Profile

A phase Phase 2a, open-label dose-ranging clinical trial to evaluate the treatment effect of different doses of ACER-001 on blood leucine and other branched-chain amino acid (BCAA) levels in MSUD patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Aug 2022 New trial record
15 Aug 2022 According to a Acer Therapeutics media release, the trial is planned to initiate in Q1 2023 subjected to IND clearance.
01 Jul 2022 According to a Acer Therapeutics media release, in July 2022, Acer submitted its IND application to the FDA for ACER-001 for the potential treatment of MSUD.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com